PMID- 9176747
OWN - NLM
STAT- MEDLINE
DCOM- 19970731
LR  - 20131121
IS  - 1120-009X (Print)
IS  - 1120-009X (Linking)
VI  - 9
IP  - 2
DP  - 1997 Apr
TI  - Chemotherapy of non small cell lung cancer. A prospectively randomized study of 
      cisplatin-etoposide versus cisplatin-mitomycin-vinblastine.
PG  - 102-5
AB  - Based on preclinical studies showing synergism between cisplatin and etoposide, 
      we randomized patients with non small cell lung cancer (NSCLC) to receive either 
      the above combination (cisplatin 100 mg/m2 day 1, etoposide 130 mg/m2 days 1-3) 
      or the combination of cisplatin-mitomycin-c and vinca drugs (MVP) (cisplatin 100 
      mg/m2, vinblastine 6 mg/m2, mitomycin 10 mg/m2 day 1), a regimen with a steady 
      response rate. Partial responses were achieved in 12/44 (27%) of the 
      cisplatin-etoposide group and in 11/43 (26%) of the MVR group. No difference in 
      median survival could be demonstrated between the two groups (36 weeks versus 38 
      weeks). Myelotoxicity and alopecia were more severe in the cisplatin-etoposide 
      group. Compared to international experience both regimens exhibited a relatively 
      low response rate. It seems that for NSCLC new agents are required.
FAU - Polyzos, A
AU  - Polyzos A
AD  - Ist Dept. of Propedeutic Medicine, Athens University School of Medicine, Laikon 
      Hospital, Greece.
FAU - Tsavaris, N
AU  - Tsavaris N
FAU - Veslemes, M
AU  - Veslemes M
FAU - Dardoufas, K
AU  - Dardoufas K
FAU - Dosios, T
AU  - Dosios T
FAU - Kosmas, C
AU  - Kosmas C
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Chemother
JT  - Journal of chemotherapy (Florence, Italy)
JID - 8907348
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Mitomycins)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Aged
MH  - Antibiotics, Antineoplastic/administration & dosage
MH  - Antineoplastic Agents, Phytogenic/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/diagnosis/*drug therapy/mortality
MH  - Cisplatin/administration & dosage
MH  - Disease Progression
MH  - Etoposide/administration & dosage
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lung Neoplasms/diagnosis/*drug therapy/mortality
MH  - Male
MH  - Middle Aged
MH  - Mitomycins/administration & dosage
MH  - Prospective Studies
MH  - Survival Rate
MH  - Vinblastine/administration & dosage
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
AID - 10.1179/joc.1997.9.2.102 [doi]
PST - ppublish
SO  - J Chemother. 1997 Apr;9(2):102-5. doi: 10.1179/joc.1997.9.2.102.